A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer | Zendy

James ChihHsin Yang | Zendy; Leah Haworth | Zendy; Richard M. Sherry | Zendy; Patrick Hwu | Zendy; Douglas J. Schwartzentruber | Zendy; Suzanne L. Topalian | Zendy; Seth M. Steinberg | Zendy; Helen X. Chen | Zendy; Steven A. Rosenberg | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer

Author(s) -

James ChihHsin Yang,

Leah Haworth,

Richard M. Sherry,

Patrick Hwu,

Douglas J. Schwartzentruber,

Suzanne L. Topalian,

Seth M. Steinberg,

Helen X. Chen,

Steven A. Rosenberg

Publication year - 2003

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa021491

Subject(s) - medicine , placebo , bevacizumab , interim analysis , vascular endothelial growth factor , gastroenterology , hazard ratio , clinical endpoint , proteinuria , renal cell carcinoma , asymptomatic , urology , surgery , oncology , randomized controlled trial , chemotherapy , kidney , pathology , confidence interval , alternative medicine , vegf receptors

Mutations in the tumor-suppressor gene VHL cause oversecretion of vascular endothelial growth factor by clear-cell renal carcinomas. We conducted a clinical trial to evaluate bevacizumab, a neutralizing antibody against vascular endothelial growth factor, in patients with metastatic renal-cell carcinoma.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research